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Abstract: Clinical prediction scores support the assessment of patients in the emergency setting to
determine the need for further diagnostic and therapeutic steps. During the current COVID-19 pandemic,
physicians in emergency rooms (ER) of many hospitals have a considerably higher patient load and need
to decide within a short time frame whom to hospitalize. Based on our clinical experiences in dealing
with COVID-19 patients at the University Hospital in Zurich, we created a triage score with the acronym
AIFELL consisting of clinical, radiological and laboratory findings. The score was then evaluated in a
retrospective analysis of 122 consecutive patients with suspected COVID-19 from March through mid-
April 2020. Descriptive statistics, Student’s t-test, ANOVA and Scheffe’s post-hoc analysis confirmed
the diagnostic power of the score. The results suggest that the AIFELL score has potential as a triage
tool in the ER setting intended to select probable COVID-19 cases for hospitalization in spontaneously
presenting or referred patients with acute respiratory symptoms.
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a  b s t r  a  c t
Clinical prediction scores support the assessment of patients in the emergency setting to
determine the need for further diagnostic and therapeutic steps. During the current COVID-
19  pandemic, physicians in emergency rooms (ER) of many hospitals have a  considerably
higher patient load and need to decide within a  short time frame whom to hospitalize. Based
on  our clinical experiences in dealing with COVID-19 patients at  the University Hospital in
Zurich, we created a  triage score with the acronym ÄIFELLc̈onsisting of clinical, radiological
and laboratory findings.
The  score was then evaluated in a  retrospective analysis of 122 consecutive patients with
suspected COVID-19 from March until mid-April 2020. Descriptive statistics, Student’s t-
test, ANOVA and Scheffe’s post-hoc analysis confirmed the diagnostic power of the score.
The results suggest that the AIFELL score has potential as a triage tool in the ER setting
intended to  select probable COVID-19 cases for hospitalization in spontaneously presenting
or  referred patients with acute respiratory symptoms.
© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an
open  access article under the  CC BY license (http://creativecommons.org/licenses/by/4.0/).
Due to the worldwide spread of SARS-CoV-2 and rapidly
increasing numbers of infections, the  novel coronavirus
became a considerable strain for emergency rooms (ER), espe-
cially when several suspected cases with unspecific general
or respiratory symptoms arrive at the  same time. Identifica-
tion of more  critical patients in the ER for hospitalization is a
challenge since the detection of SARS-CoV-2 in nasopharyn-
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geal swabs by quantitative polymerase chain reaction (qPCR)
still requires many hours (>6 h in our setting). Therefore, the
qPCR result currently cannot be used in the  frontline setting
to decide whom to  hospitalize and who can be managed as
an outpatient. Rapid point of care tests for SARS-CoV-2 were
being developed at the time of the study but were not validated
for routine use.1
https://doi.org/10.1016/j.bjid.2020.07.003
1413-8670/© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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Table 1 – Distribution of included patients and their clinically assigned AIFELL scores.
Consecutive patients with suspected COVID-19 admitted via the ER  from March through mid-April 2020
(n = 122; 72 males, 50 females)
Nasopharyngeal qPCR result SARS-CoV-2 positive (n = 70, age
60.6 years ± 14.2)
SARS-CoV-2 negative (n =  52, 57.9
years ±  17.9)
Components of the AIFELL score: Altered smell or taste (yes/no),
Inflammation (CRP ≥ 30 mg/L), Infiltrates (yes/no), Fever (≥  38◦ C),
Elevated LDH (>400 U/L), Lymphocytopenia (absolute count < 1.45 G/L)
Diagnosis COVID-19 Stage I
(n = 10)
COVID-19 Stage
IIa (n =  31)
COVID-19 Stage
IIb (n  =  29)
Other respiratory problems like
exacerbated COPD, bronchial asthma,
bacterial pneumonia, aspiration
pneumonitis, other viral infections
(influenza, metapneumovirus), cardiac
failure
Mean AIFELL score 1.8  ±  0.8 4.6 ±  0.8 2.2  ± 1.1
4.19 ±  1.28
Total number n AIFELL positive (4–6 points) 0 29 (93.5%) 29 (100%) 5  (9.6%)
Total number n AIFELL negative (0 –  3  points) 10 (100%) 2  (6.5%) 0  47 (90.4%)
Legend: Results given as  mean ± SD  unless indicated otherwise. Stage III patients with progressive systemic inflammation were usually admitted
directly to  ICU from normal ward or other hospitals in our setting, not through the ER. Therefore, they are not mentioned in this table. SD,
standard deviation.
As a frontline physician, whose task was to evaluate and
triage patients arriving with symptoms suggesting COVID-19
in the ER coronavirus unit of the University Hospital in  Zurich,
the first author was confronted with the problem of whom
to choose for hospitalization due to probable COVID-19 and
whom to discharge whilst the qPCR results of the swab  were
pending.
The hospitalization criterion was  to select patients at risk
for developing more  severe symptoms leading to respiratory
failure (COVID Stages II or III2). During clinical routine work in
the frontline unit, the question of a score arose to support
the triage process and to assist other physicians in  similar
situations.
We therefore followed up consecutively hospitalized
patients with proven COVID-19 in order to determine initial
features which may help distinguishing probable COVID-
19 cases from other respiratory problems. In 30 personally
encountered consecutively hospitalized patients with qPCR-
proven COVID-19 studied initially as a pilot cohort, we found
that elevated C-reactive protein (CRP) and lactate dehy-
drogenase (LDH) levels as well as lymphocytopenia were
characteristic laboratory patterns. Evidence obtained from
literature searches using the keywords “COVID-19”, “SARS-
CoV-2”, “laboratory” and “patients” in PubMed proved that
these laboratory abnormalities were associated with COVID-
19.3–5 Additionally, most patients in  the pilot cohort presented
with an elevated body temperature and showed unilateral or
bilateral pulmonary infiltrates in conventional chest radio-
graphy. Several patients mentioned spontaneously having
noted an attenuation of smell or taste and this symptom,
although not widely recognized as  a typical feature at the  time,
was  considered to be COVID-19-associated.6 When the rele-
vant paraclinical components were analyzed, cut-off values
became more  evident and a simple score was created based
on typical clinical information routinely available in our ER.
The AIFELL score includes an Altered sense of smell/taste,
Inflammation (C-reactive protein ≥30 mg/L), radiological
Infiltrates, Fever (≥38.0 ◦ C), Elevated Lactate dehydrogenase
(LDH) levels (>400 U/L) and Lymphocytopenia (absolute count
<1.45 G/L). The score is calculated by adding the number of
criteria met  at initial presentation in the ER, whereas each
criterion equals one point (score range from 0 to 6  points).
To assess the score, we applied it retrospectively to consec-
utive patients with suspected COVID-19 admitted via the ER
from March until mid-April 2020. Only those cases evaluated
with chest imaging and a  blood test including at least two of
the three considered blood parameters at presentation in the
ER, who did not decline the general research consent, were
included. Of 122 patients with suspected COVID-19, 52  cases
turned out to have other respiratory problems.
SARS-CoV-2 positive patients (n = 70) were classified
according to the stages suggested by Siddiqi and Mehra (Sup-
plementary Figure S.1).2
The study was approved by the Institutional Review Board
of the  Canton of Zurich (Cantonal Ethics Committee, Nr.  2020-
00854). After testing for normal distribution and standardized
outliers, we created a new variable named “paraclinical mea-
surements” by including the z-standardized mean values of
LDH, CRP, inversely poled serum lymphocytes and auricular
body temperature. We  afterwards summarized this variable
with lung infiltrates seen by imaging and alterations of
smell/taste indicated by patient history to get our predic-
tor  score named “AIFELL”. Student’s t-tests and an  ANOVA
with Scheffe’s post-hoc tests were performed for group com-
parisons. For  all analyses, we  used MS  Excel 2016 and SPSS
24.
The mean age of our SARS-CoV-2 positive subjects (n = 70)
was 60.6 years ± 14.2 (standard deviation) vs. 57.9 years ± 17.9
of our SARS-CoV2 negative subjects (n = 52; t  = .908; p = 0.37).
There were significantly different AIFELL scores before and
after z-standardization (t = 5.77, p < 0.001) between SARS-CoV-2
positive patients (mean = 2.43 ±  0.15 standard error) and SARS-
CoV-2 negative patients (mean = 1.30 ± 0.12) (Supplementary
Figure S.2).
A score of ≥4 points/criteria met  at presentation was
highly associated with qPCR-based SARS-CoV-2 detection
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Table 2 – ANOVA of intergroup differences of the AIFELL score groups (1–6) using objective paraclinical measurements or
the whole array of AIFELL components.
Paraclinical measurements Whole array of AIFELL components




 of positive components = points Mean ± SD n df = 116,  F = 10.55,
p  < 0.0001
Mean  ± SD  n df = 116, F  = 31.525,
p < 0.0001
1  −0.54 ±  0.28 12  1  < 2; 1  < 3; 1
< ***4; 1 <  *5; 1
<  **6
0.79 ± 0.93 12 1 < *4; 1 <  *5; 1
< *6; 1 < 2; 1 < 3
2 −0.21 ±  0.43 26  2  < 3; 2  < 4; 2 < *5;
2  < 6
1.18 ± 0.55 26 2 < 3; 2 < *4; 2  < *
5; 2 < *6
3 −0.04 ±  0.32 16  3  < 5; 3  < 6  1.66 ± 0.67 16 3 < **5;  3  < *6;
4 0.01 ± 0.65 31  4  < **5; 4 < 6 2.21 ± 0.93 31 4 < 5; 4 < *6
5 0.52 ± 0.42 24  2.77 ± 0.83 24
6 0.30 ± 0.38 8 4.30 ± 0.38 8
Legend: Paraclinical measurements =  z-standardized mean values of  serum LDH, CRP, inverse absolute lymphocyte count and temperature
measured auricularly. Whole array of AIFELL components = sum of  paraclinical measurements, lung infiltrates and altered smell or  taste.
*p < .001; **p  < .01; ***p  =  .04. In only  86  of the  122 included cases, LDH values were determined. Smell and taste alterations were actively mentioned
by the patients and not routinely asked by the physicians. Therefore, the  number of  positive cases is  only  19.  Patients without any positive
components relating to the  AIFELL score (0, n  = 5) were not  included in statistical group comparisons. LDH, lactate dehydrogenase; CRP,
C-reactive protein; SD, standard deviation.
in nasopharyngeal swabs and development of symptomatic
COVID-19 (Stages II or III), thus justifying hospitalization.
Scores between 0 and 3 were associated with other respiratory
conditions (Table 1).
Stage III patients (severe disease) with extra-pulmonary
systemic hyperinflammation, ARDS or symptoms of shock
were usually transferred to intensive care unit (ICU) from nor-
mal  wards or from other hospitals. Documented cases of ICU
transfers of patients who deteriorated in the  course of disease
(progression from Stage II to Stage III) during the hospital stay
(n = 14) showed mean AIFELL scores at the day of admission to
ICU of 5 ± 0.68.
The ANOVA and post-hoc calculations were performed
to substantiate group differences more  clearly and verified
significant differences of evaluated score component values
between different score values (Table 2). We  found, for exam-
ple, that the group of patients with an  AIFELL score of 5 points
had higher paraclinical component values than the group with
2 points (p < 0.001). Using the whole array of AIFELL compo-
nents, it could be  shown that the group with 6  points had
significantly higher AIFELL component values than the group
with 3 points (p < 0.0001).
Based on the evaluation of the initial data of 30 patients,
we generated the AIFELL score as  a  simple triage instrument
for the ER setting consisting of frequently available elements
like patient symptoms (fever, altered smell or taste), laboratory
tests (differential blood count, CRP, LDH) and imaging. After-
wards, we  evaluated its diagnostic performance in a larger
number of consecutive patients hospitalized for suspected
COVID-19.
A host risk score dealing with comorbidities of COVID-
19 patients7 as  well as  scores predicting critical illness8
or hyperinflammation9 in hospitalized patients with proven
COVID-19 have been previously published. However, no ER
triage score to identify probable COVID-19 cases in more  criti-
cal stages (II and III) has been proposed yet. The AIFELL score
uses only frequently obtained data usually available both, in
the ER and the general practice setting. Other additional lab-
oratory parameters like  ferritin, troponin10 and D-dimers,11
which are elevated in  severe cases of COVID-19,12 as well as
more  sophisticated parameters such as  interleukin (IL)-611
and soluble IL-2 receptor13 may  also be of interest, but are
not routinely evaluated or are  not widely available. There-
fore, these additional parameters are less applicable for ER or
general practice triage purposes.
During the  COVID-19 pandemic and partly scarce medical
resources, the AIFELL score may  be useful for selecting symp-
tomatic COVID-19 cases from patients with rather unspecific
general or respiratory symptoms in the ER or general practice
setting who should immediately get a SARS-CoV-2 swab due
to  higher probability of the disease. The score is not intended
to identify asymptomatic or oligosymptomatic SARS-CoV-2
infections (COVID-19 Stage I), which generally can be dealt
with in the outpatient setting.
The major limitation of this work is the single-center
evaluation of only a  limited number of patients. Due  to its
retrospective nature, some values were not obtained from all
patients. For example, in 36 of all included cases LDH val-
ues were missing as it was not measured in every admitted
patient. Smell and taste alterations were actively mentioned
by the  patients and not routinely asked by the physicians dur-
ing the study period.
The strengths of the AIFELL score are its simplicity, imme-
diate availability as well  as  wide applicability due to simple
components. The AIFELL score obviously needs to be prospec-
tively applied in larger cohorts of patients to gain more  reliable
data regarding its diagnostic yield.
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